文献速递自身免疫性与大疱性皮肤病毛发、甲与色素性疾病

Upadacitinib治疗成人及青少年重度斑秃:两项三期UP-AA随机临床试验

Upadacitinib for Severe Alopecia Areata in Adults and Adolescents: Two Phase 3 UP-AA Randomized Clinical Trials.
PubMed 文献 · JAMA Dermatol · 2026-01-01

两项平行三期随机对照试验(UP-AA1和UP-AA2)评估口服选择性JAK抑制剂upadacitinib治疗12至<64岁重度斑秃(SALT≥50)患者。第24周时,15mg和30mg组达到SALT≤20的比例显著高于安慰剂组,安全性特征与已批准适应症一致,未发现新的安全性信号。

要点

  • upadacitinib 15mg和30mg在第24周显著提高重度斑秃患者SALT≤20应答率。
  • 两项试验中15mg组SALT≤20比例分别为45.2%和44.6%,30mg组为55.0%和54.3%,安慰剂组为1.5%和3.4%。
  • 安全性特征在成人和青少年中相似,常见不良事件包括上呼吸道感染、痤疮等。

核心结论

  • 在两项三期随机对照试验中,upadacitinib在重度斑秃成人和青少年中显示正向获益-风险特征,可能成为潜在有效治疗选择。

研究设计与样本

  • 全球临床项目包含两项平行三期重复随机对照试验(UP-AA1和UP-AA2),于2023年10月至2025年7月开展。
  • 纳入12至<64岁重度斑秃患者(SALT评分≥50),随机2:2:1分配至每日一次upadacitinib 15mg、30mg或安慰剂。
  • 两项试验均包括24周安慰剂对照双盲治疗期(A期)和28周盲法扩展治疗期(B期)。
  • 共随机1399例患者(平均年龄36岁,范围12-64;女性826例,59.0%),UP-AA1组676例,UP-AA2组723例。
  • 基线平均(SD)SALT评分为83.9(18.9)。

主要发现

  • 第24周达到SALT≤20的患者比例:UP-AA1中15mg组122例(45.2%)、30mg组149例(55.0%)、安慰剂组2例(1.5%);UP-AA2中15mg组129例(44.6%)、30mg组157例(54.3%)、安慰剂组5例(3.4%)。
  • 两种剂量在成人和青少年中的安全性特征相似,与已批准适应症一致,未发现新的安全性发现。
  • 任何治疗组中报告率>5%的治疗中出现的不良事件包括上呼吸道感染、痤疮、血肌酸磷酸激酶升高和鼻咽炎。
  • 两项研究合计,治疗中出现的严重不良事件在15mg组9例(1.6%)、30mg组13例(2.3%)、安慰剂组1例(0.4%)中发生。

关键数值与推荐

  • 主要终点为第24周达到SALT评分≤20(多重控制)。
  • 多重控制次要疗效终点包括眉毛和睫毛临床医生报告结局改善、第4/8/12周SALT≤20、SALT≤10、第24周SALT=0、第4和24周患者总体印象变化评分为非常改善或中度改善、第24周其他斑秃特异性健康相关生活质量指标。

临床怎么用

  • 对于12岁及以上重度斑秃患者,upadacitinib 15mg或30mg每日一次可能作为系统治疗选择。
  • 治疗前需评估基线SALT评分,治疗中监测SALT变化及不良事件如感染、痤疮和肌酸磷酸激酶升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Alopecia areata (AA) is a chronic, systemic immune-mediated disease characterized by nonscarring hair loss. Many patients do not experience improvements with available treatment options and only ritlecitinib is approved for adolescent patients; therefore, there remains a clear unmet need for additional and improved systemic therapies. OBJECTIVE: To evaluate the efficacy and safety of upadacitinib-an oral selective Janus kinase inhibitor-in adult and adolescent patients with severe AA. DESIGN, SETTING, AND PARTICIPANTS: This global clinical program included 2 parallel phase 3 replicate randomized clinical trials (UP-AA1 and UP-AA2) conducted from October 2023 to July 2025, to evaluate upadacitinib in adolescent and adult patients (age 12 to <64 years old) with severe AA, defined as a Severity of Alopecia Tool (SALT) score of 50 or greater. Both trials included a 24-week placebo-controlled, double-blinded treatment period (period A) and a 28-week blinded extension treatment period (period B). Data were analyzed from July 2025 to October 2025. INTERVENTIONS: Eligible patients were randomized 2:2:1 to once daily 15- or 30-mg upadacitinib or matching placebo. MAIN OUTCOMES AND MEASURES: Achievement of (multiplicity controlled) SALT score of 20 or less at week 24. Multiplicity-controlled secondary efficacy end points included achievement of improvements in clinician-reported outcomes for eyebrows and eyelashes; achievement of SALT scores of 20 or less at weeks 4, 8, and 12; achievement of SALT score of 10 or less; SALT score 0 at week 24; patients' global impression of change of AA score of much better or moderately better at weeks 4 and 24; and other AA-specific health-related quality of life measures at week 24. RESULTS: A total of 1399 patients were randomized (mean [range] age, 36 [12-64] years; 826 female [59.0%]), 676 patients from the UP-AA1 and 723 patients from the UP-AA2, to either 15-mg upadacitinib (270 and 289 patients, respectively), 30-mg upadacitinib (271 and 289), or placebo (135 and 145). Their mean (SD) SALT score was 83.9 (18.9) at baseline. The proportion of patients who achieved SALT score of 20 or less at week 24 was significantly higher for the 15-mg upadacitinib (122 [45.2%] and 129 [44.6%]) and the 30-mg upadacitinib (149 [55.0%] and 157 [54.3%]) groups, respectively, than for the placebo (2 [1.5%] and 5 [3.4%]) group. The safety profile of both doses was similar in adults and adolescents and consistent with approved indications; no new safety findings were identified. Treatment-emergent adverse events reported by more than 5% of patients in any treatment group were upper respiratory tract infection, acne, elevated blood creatine phosphokinase, and nasopharyngitis. Across both studies, treatment-emergent serious adverse events occurred in 9 (1.6%), 13 (2.3%), and 1 (0.4%) of patients receiving 15-mg upadacitinib , 30-mg upadacitinib, or placebo, respectively. CONCLUSIONS AND RELEVANCE: In these 2 parallel phase 3 replicate randomized clinical trials, upadacitinib demonstrated a positive benefit-risk profile in adults and adolescents with severe AA. Upadacitinib may be a potentially effective treatment option for this patient population. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06012240.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Mostaghimi A, Gooderham MJ, Lynde C, et al. Upadacitinib for Severe Alopecia Areata in Adults and Adolescents: Two Phase 3 UP-AA Randomized Clinical Trials. JAMA Dermatol. 2026. PMID: 42584887. doi:10.1001/jamadermatol.2026.2853

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。